Literature DB >> 894913

Origin of hypercholesterolemia in chronic experimental nephrotic syndrome.

A C Goldberg, F G Eliaschewitz, E C Quintão.   

Abstract

Sixteen nephrotized rats and eight controls were submitted to a continuous sterol balance for two weeks. During the whole experiment (two months) the rats were pair-fed a balanced sterol-free diet and their proteinuria regularly measured as a parameter of the nephrotic state. Serum cholesterol and albumin were also measured at the end of the experiment. Liver and carcass (excluding intestine and central nervous system) as well as feces were submitted to sterol analysis by gas-liquid chromatography. Sterol losses were corrected for by adding radioactive cholesterol and cholic acid at the beginning of the methodological procedures. The results showed that while fecal sterol excretion was similar in the nephrotic group as compared to controls, a definite increase in serum, carcass, and liver cholesterol was observed in the nephrotic animals, indicating that a real enhancement of synthesis had occurred. The meaning of increased cholesterol hepatic content is discussed, as well as the possible relationship between enhanced protein and cholesterol hepatic synthesis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 894913     DOI: 10.1038/ki.1977.75

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

2.  Lipoprotein profiles at different stages of the nephrotic syndrome.

Authors:  U Querfeld; A Gnasso; W Haberbosch; J Augustin; K Schärer
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

3.  Influence of the Alcohol Present in a Phytotherapic Tincture on Male Rat Lipid Profiles and Renal Function.

Authors:  Fernanda Coleraus Silva; Juliete Gomes de Lara de Souza; Alana Meira Reichert; Renata Prestes Antonangelo; Rodrigo Suzuki; Ana Maria Itinose; Carla Brugin Marek
Journal:  Evid Based Complement Alternat Med       Date:  2015-12-28       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.